×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).
The optimal length of time to wait to initiate treatment for patients with chronic lymphocytic leukemia (CLL), as well as the length of time to remain on treatment, are described by Nicole Lamanna, M.D.
With regard to cytogenetic testing, molecular testing, and imaging, Nicole Lamanna, M.D., outlines what testing should be completed alongside a diagnosis of chronic lymphocytic leukemia (CLL).
Kristie L. Kahl
The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.
Brielle Benyon
The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
Chuck Pagano
Former NFL coach discusses how cancer motivated him to appreciate life.
Kristie L. Kahl
This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.
Brielle Benyon
Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.
Brielle Benyon
Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.
Brielle Benyon
The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.